Loading ...TORONTO — Transition Therapeutics Inc. today announced the results from a Phase 2 clinical study of gastrin analogue, TT-223, in patients with type 2 diabetes. Patients who received the highest daily dose of TT-223 for 12 weeks and completed the entire study without adjusting their diabetes therapies experienced a statistically significant reduction in HbA1c of 1.13%, 6 months after completing …
Popular
type 2 diabetes type 1 diabetes Diabetes Complications diabetes research diabetes management managing diabetes JDRF diabetes support american diabetes association Diabetes Community women's health obesity type 2 diabetes risk children's health type 2 diabetes prevention kids with diabetes diabetes type 2 diabetes treatment insulin diabetes treatment obesity epidemic insulin resistance juvenile diabetes children with diabetes Tanya Zuckerbrot